Sodium‑glucose cotransporter 2 inhibitors (SGLT2i): renal implications

Type 2 diabetes mellitus (DM2) is a chronic condition that affects more than 400 million individuals worldwide. In DM2 patients, an appropriate glycemic control slows the onset and delays the progression of all its micro and macrovascular complications. Even though there are several glucose-lowering...

Descripción completa

Detalles Bibliográficos
Autores: Castañeda, Alejandrina M., Dutra‑Rufato, Amanda, Juarez, Maria J., Grosembacher, Luis, Gonzalez‑Torres, Henry, Musso, Carlos G.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:Colombia
Institución:Universidad Simón Bolívar
Repositorio:Repositorio Digital USB
Idioma:inglés
OAI Identifier:oai:bonga.unisimon.edu.co:20.500.12442/6244
Acceso en línea:https://hdl.handle.net/20.500.12442/6244
https://doi.org/10.1007/s11255-020-02585-w
Access Level:acceso abierto
Palabra clave:SGLT2i
Kidney
Glucosuria
id CO_a59c7aeb6d4e685bbeec087e094ffb4c
oai_identifier_str oai:bonga.unisimon.edu.co:20.500.12442/6244
network_acronym_str CO
network_name_str Colombia
repository_id_str
spelling Sodium‑glucose cotransporter 2 inhibitors (SGLT2i): renal implicationsCastañeda, Alejandrina M.Dutra‑Rufato, AmandaJuarez, Maria J.Grosembacher, LuisGonzalez‑Torres, HenryMusso, Carlos G.SGLT2iKidneyGlucosuriaType 2 diabetes mellitus (DM2) is a chronic condition that affects more than 400 million individuals worldwide. In DM2 patients, an appropriate glycemic control slows the onset and delays the progression of all its micro and macrovascular complications. Even though there are several glucose-lowering drugs, only approximately half of patients achieve glycemic control, while undesirable adverse effects (e.g., low serum glucose) normally affect treatment. Therefore, there is a need for new types of treatments. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have just been developed for treating DM2. Renal hyperfiltration as a marker of increased intraglomerular pressure in diabetic patients, and the role of renin–angiotensin– aldosterone system (RAAS) in this phenomenon have been studied. Nevertheless, RAAS blockade does not completely reduce hyperfiltration or diabetic renal damage. In this sense, the contribution of renal tubular factors to the hyperfiltration state, including sodium–glucose cotransporter (SGLT), has been currently studied. SGLT2i reduce proximal tubular sodium reabsorption, therefore increasing distal sodium delivery to the macula densa, causing tubule-glomerular feedback activation, afferent vasoconstriction, and reduced hyperfiltration in animal models. In humans, SGLT2i was recently shown to reduce hyperfiltration in normotensive, normoalbuminuric patients suffering from type 1 diabetes mellitus. In DM2 clinical trials, SGLT2 is associated with significant hyperfiltration and albuminuria reduction. The aim of this article is to compile the information regarding SGLT2i drugs, emphasizing its mechanism of renal repercussion.Springer2020-08-10T16:48:01Z2020-08-10T16:48:01Z2020info:eu-repo/semantics/articleArtículo científicoinfo:eu-repo/semantics/publishedVersionpdfapplication/pdf15732584https://hdl.handle.net/20.500.12442/6244https://doi.org/10.1007/s11255-020-02585-wInternational Urology and NephrologyVol. 38 N° 8, (2020)reponame:Repositorio Digital USBinstname:Universidad Simón Bolívarinstacron:Universidad Simón BolívarengAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccess2021-04-06T12:24:04Z
dc.title.none.fl_str_mv Sodium‑glucose cotransporter 2 inhibitors (SGLT2i): renal implications
title Sodium‑glucose cotransporter 2 inhibitors (SGLT2i): renal implications
spellingShingle Sodium‑glucose cotransporter 2 inhibitors (SGLT2i): renal implications
Castañeda, Alejandrina M.
SGLT2i
Kidney
Glucosuria
title_short Sodium‑glucose cotransporter 2 inhibitors (SGLT2i): renal implications
title_full Sodium‑glucose cotransporter 2 inhibitors (SGLT2i): renal implications
title_fullStr Sodium‑glucose cotransporter 2 inhibitors (SGLT2i): renal implications
title_full_unstemmed Sodium‑glucose cotransporter 2 inhibitors (SGLT2i): renal implications
title_sort Sodium‑glucose cotransporter 2 inhibitors (SGLT2i): renal implications
dc.creator.none.fl_str_mv Castañeda, Alejandrina M.
Dutra‑Rufato, Amanda
Juarez, Maria J.
Grosembacher, Luis
Gonzalez‑Torres, Henry
Musso, Carlos G.
author Castañeda, Alejandrina M.
author_facet Castañeda, Alejandrina M.
Dutra‑Rufato, Amanda
Juarez, Maria J.
Grosembacher, Luis
Gonzalez‑Torres, Henry
Musso, Carlos G.
author_role author
author2 Dutra‑Rufato, Amanda
Juarez, Maria J.
Grosembacher, Luis
Gonzalez‑Torres, Henry
Musso, Carlos G.
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv SGLT2i
Kidney
Glucosuria
topic SGLT2i
Kidney
Glucosuria
description Type 2 diabetes mellitus (DM2) is a chronic condition that affects more than 400 million individuals worldwide. In DM2 patients, an appropriate glycemic control slows the onset and delays the progression of all its micro and macrovascular complications. Even though there are several glucose-lowering drugs, only approximately half of patients achieve glycemic control, while undesirable adverse effects (e.g., low serum glucose) normally affect treatment. Therefore, there is a need for new types of treatments. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have just been developed for treating DM2. Renal hyperfiltration as a marker of increased intraglomerular pressure in diabetic patients, and the role of renin–angiotensin– aldosterone system (RAAS) in this phenomenon have been studied. Nevertheless, RAAS blockade does not completely reduce hyperfiltration or diabetic renal damage. In this sense, the contribution of renal tubular factors to the hyperfiltration state, including sodium–glucose cotransporter (SGLT), has been currently studied. SGLT2i reduce proximal tubular sodium reabsorption, therefore increasing distal sodium delivery to the macula densa, causing tubule-glomerular feedback activation, afferent vasoconstriction, and reduced hyperfiltration in animal models. In humans, SGLT2i was recently shown to reduce hyperfiltration in normotensive, normoalbuminuric patients suffering from type 1 diabetes mellitus. In DM2 clinical trials, SGLT2 is associated with significant hyperfiltration and albuminuria reduction. The aim of this article is to compile the information regarding SGLT2i drugs, emphasizing its mechanism of renal repercussion.
publishDate 2020
dc.date.none.fl_str_mv 2020-08-10T16:48:01Z
2020-08-10T16:48:01Z
2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
Artículo científico
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv 15732584
https://hdl.handle.net/20.500.12442/6244
https://doi.org/10.1007/s11255-020-02585-w
identifier_str_mv 15732584
url https://hdl.handle.net/20.500.12442/6244
https://doi.org/10.1007/s11255-020-02585-w
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv pdf
application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv International Urology and Nephrology
Vol. 38 N° 8, (2020)
reponame:Repositorio Digital USB
instname:Universidad Simón Bolívar
instacron:Universidad Simón Bolívar
instname_str Universidad Simón Bolívar
instacron_str Universidad Simón Bolívar
institution Universidad Simón Bolívar
reponame_str Repositorio Digital USB
collection Repositorio Digital USB
_version_ 1825051216330096640
score 15,811543

Similares en LA Referencia